Moreover, the combination of PD-L1 inhibitors and paclitaxel markedly enhanced the recruitment of CD8+ tumor-infiltrating lymphocytes (TILs), thereby inhibiting the tumor growth of lung adenocarcinoma in mice[57]. Here, CD8A is linked to neoplasm.